This program has the potential to advance an off-the-shelf allogeneic CAR-T cell therapy and provide a new treatment option for relapsed CD7-positive T-cell malignancies such as T-ALL/LBL, which represent a significant unmet medical need. Here, CD7 is linked to acute lymphoblastic leukemia.